About Us
Our Company
Leadership
Contact
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline LTX-315
R & D
Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Menu
About Us
Our Company
Leadership
Contact
Product
Candidates
Pipeline VP-102
Pipeline VP-103
Pipeline LTX-315
R & D
Publications
Investors &
Media
Investor Overview
Press Releases
Analyst Coverage
Presentations & Events
Stock Information
SEC Filings
Corporate Governance
Investor FAQs
Investor Connection
Careers
Press Releases
Press Releases
Year
2018
2019
2020
July 23, 2020
Verrica Pharmaceuticals Announces Dr. Lawrence Eichenfield Joins Board of Directors
July 23, 2020
Verrica Pharmaceuticals Announces Clinical and Drug Development Leadership Changes
July 14, 2020
Verrica Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
June 29, 2020
Verrica Pharmaceuticals Provides Regulatory Update on VP-102
June 12, 2020
Verrica Pharmaceuticals Announces Positive Results from Two New Pooled Analyses of the Phase 3 CAMP Trials of VP-102 in Molluscum Contagiosum
< previous
1
2
3
4
next >
